Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data
- PMID: 35232230
- DOI: 10.2217/fon-2021-1102
Effectiveness of crizotinib versus entrectinib in ROS1-positive non-small-cell lung cancer using clinical and real-world data
Abstract
Aims: To compare clinical trial results for crizotinib and entrectinib in ROS1-positive non-small-cell lung cancer and compare clinical trial data and real-world outcomes for crizotinib. Patients & methods: We analyzed four phase I-II studies using a simulated treatment comparison (STC). A STC of clinical trial versus real-world evidence compared crizotinib clinical data to real-world outcomes. Results: Adjusted STC found nonsignificant trends favoring crizotinib over entrectinib: objective response rate, risk ratio = 1.04 (95% CI: 0.85-1.28); median duration of response, mean difference = 16.11 months (95% CI: -1.57- 33.69); median progression-free survival, mean difference = 3.99 months (95% CI: -6.27-14.25); 12-month overall survival, risk ratio = 1.01 (95% CI: 0.90-1.12). Nonsignificant differences were observed between the trial end point values and the real-world evidence for crizotinib. Conclusions: Crizotinib and entrectinib have comparable efficacy in ROS1-positive non-small-cell lung cancer.
Keywords: ROS1; RWE; STC; comparative effectiveness; crizotinib; entrectinib; non-small-cell lung cancer; real-world evidence; simulated treatment comparison.
Similar articles
-
Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.Int J Mol Sci. 2023 Jul 15;24(14):11495. doi: 10.3390/ijms241411495. Int J Mol Sci. 2023. PMID: 37511255 Free PMC article. Review.
-
Comparative effectiveness analysis between entrectinib clinical trial and crizotinib real-world data in ROS1+ NSCLC.J Comp Eff Res. 2021 Dec;10(17):1271-1282. doi: 10.2217/cer-2021-0131. Epub 2021 Aug 24. J Comp Eff Res. 2021. PMID: 34427452
-
Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.J Comp Eff Res. 2020 Aug;9(12):861-876. doi: 10.2217/cer-2020-0063. Epub 2020 Jul 10. J Comp Eff Res. 2020. PMID: 32648475
-
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.Lancet Oncol. 2020 Feb;21(2):261-270. doi: 10.1016/S1470-2045(19)30690-4. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838015 Free PMC article.
-
Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.Drugs. 2019 Aug;79(12):1277-1286. doi: 10.1007/s40265-019-01164-3. Drugs. 2019. PMID: 31313100 Review.
Cited by
-
CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines highlight differential drug sensitivity in 2D vs 3D cultures while reflecting established resistance profiles.J Transl Med. 2024 Mar 3;22(1):234. doi: 10.1186/s12967-024-04988-0. J Transl Med. 2024. PMID: 38433235 Free PMC article.
-
Entrectinib Response to ROS1-Fusion-Positive Non-Small-Cell Lung Cancer That Progressed on Crizotinib with Leptomeningeal Metastasis: A Case Report.Case Rep Oncol. 2023 Dec 12;16(1):1558-1567. doi: 10.1159/000534549. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 38089732 Free PMC article.
-
Therapeutical Options in ROS1-Rearranged Advanced Non Small Cell Lung Cancer.Int J Mol Sci. 2023 Jul 15;24(14):11495. doi: 10.3390/ijms241411495. Int J Mol Sci. 2023. PMID: 37511255 Free PMC article. Review.
-
Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications.MedComm (2020). 2023 May 2;4(3):e261. doi: 10.1002/mco2.261. eCollection 2023 Jun. MedComm (2020). 2023. PMID: 37143582 Free PMC article. Review.
-
Efficacy of crizotinib retreatment after crizotinib-related interstitial lung disease in a patient with ROS1-rearranged advanced lung adenocarcinoma: A case report and potential crizotinib retreatment strategy.Front Oncol. 2022 Oct 18;12:900966. doi: 10.3389/fonc.2022.900966. eCollection 2022. Front Oncol. 2022. PMID: 36330497 Free PMC article.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
